Results of the SUSTAIN-6 trial (ClinicalTrials.gov Identifier: NCT01720446) published in 2016 were among the first to suggest that there may be microvascular complications associated with GLP-1 RA use ...

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite ...

She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which ...

Understanding the GLP-1 consumer. Getting to know GLP-1 consumers is becoming a high priority for the food and beverage industry, as their numbers rise and buying power grows. Now a new report from ...

Over three years of follow-up between 2020 and 2023, 0.2% (93 patients) of those in the GLP-1 user group were diagnosed with nAMD, as were 0.1% (88 patients) in the contrasting group.

Data were included for 85,015 adults with a body mass index ≥30 kg/m 2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023.

GLP-1 medications have demonstrated benefits beyond weight loss, including reducing the risk of heart disease and slowing the progression of kidney disease in certain populations.

GLP-1 receptor agonist users had a significant 39% higher risk of requiring KRT (95% CI, 1.19-1.63) compared with SGLT2 inhibitor users, Dr Chang’s team reported in the American Journal of ...

People taking such GLP-1 drugs lost just under 9% of their body weight on average after a year, researchers reported June 10 in the journal Obesity.. That’s far less than the 15% to 21% body ...